Nebcina (Tobramycin)

Tobramycin, the active ingredient in Nebcina, is an aminoglycoside antibiotic presented as an injectable solution for intramuscular and intravenous use. It treats serious gram‑negative bacterial infections, including those caused by Pseudomonas aeruginosa, in hospitalized patients. It is indicated for severe infections where other agents may be ineffective, and is administered under professional supervision.

GNH USA supplies Nebcina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing reliable, quality‑assured products to meet global healthcare needs.

Tobramycin is an aminoglycoside antibiotic used to treat infections caused by gram‑negative bacteria. - Gram‑negative sepsis: provides bactericidal activity against a broad range of susceptible organisms. - Pseudomonas aeruginosa infections: effective for severe infections such as pneumonia, bloodstream infections, and wound infections caused by P. aeruginosa. - Hospital‑acquired pneumonia: used in combination therapy to target resistant gram‑negative pathogens in critically ill patients.

Tobramycin may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nephrotoxicity: reversible increase in serum creatinine or reduced renal function. - Ototoxicity: high‑frequency hearing loss that may be temporary. - Injection site reactions: pain, erythema, or mild swelling. Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring emergency treatment. - Permanent hearing loss: irreversible auditory damage. - Severe renal failure: acute kidney injury unresponsive to dose changes.

When using Tobramycin, careful monitoring and specific precautions help reduce the risk of toxicity. - Renal function monitoring: assess serum creatinine and urine output before and during therapy. - Auditory function monitoring: perform baseline and periodic hearing tests, especially in prolonged treatment. - Avoid use in patients with known hypersensitivity to aminoglycosides. - Use caution in neonates, the elderly, and patients with pre‑existing renal impairment. - Adjust dose in patients with reduced creatinine clearance to prevent accumulation. - Store at ambient temperature: keep in original container, protect from moisture and light.

Tobramycin can interact with several medicines, altering its efficacy or increasing toxicity. Major Interactions (Avoid): - Loop diuretics (e.g., furosemide): synergistic ototoxicity. - Neuromuscular blocking agents (e.g., pancuronium): enhanced muscle weakness. - Concurrent use of other aminoglycosides: additive nephrotoxicity. Moderate Interactions (Monitor Closely): - Vancomycin: combined risk of renal impairment. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased potential for kidney injury. - Cephalosporins: possible antagonistic effect reducing antibacterial activity.